Xiaowei Xu

3.7k total citations · 1 hit paper
33 papers, 2.0k citations indexed

About

Xiaowei Xu is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Xiaowei Xu has authored 33 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 13 papers in Hepatology and 9 papers in Infectious Diseases. Recurrent topics in Xiaowei Xu's work include Liver Disease Diagnosis and Treatment (13 papers), Liver Disease and Transplantation (8 papers) and Hepatitis B Virus Studies (8 papers). Xiaowei Xu is often cited by papers focused on Liver Disease Diagnosis and Treatment (13 papers), Liver Disease and Transplantation (8 papers) and Hepatitis B Virus Studies (8 papers). Xiaowei Xu collaborates with scholars based in China and United States. Xiaowei Xu's co-authors include Lanjuan Li, Kaijin Xu, Yunqing Qiu, Xiaoxin Wu, Hainv Gao, Jifang Sheng, Shibo Li, Sheng Zhang, Huaying Wang and Hongliu Cai and has published in prestigious journals such as PLoS ONE, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Xiaowei Xu

31 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

2020 1.5k citations Xiaowei Xu, Xiaoxin Wu et al. BMJ profile →

Peers

Countries citing papers authored by Xiaowei Xu

Since Specialization

Citations

This map shows the geographic impact of Xiaowei Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaowei Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaowei Xu more than expected).

Fields of papers citing papers by Xiaowei Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaowei Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaowei Xu. The network helps show where Xiaowei Xu may publish in the future.

Co-authorship network of co-authors of Xiaowei Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaowei Xu. A scholar is included among the top collaborators of Xiaowei Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaowei Xu. Xiaowei Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity and overcomes resistance in acute myeloid leukemia 2025 ·Acta Pharmacologica Sinica ·Yujun Chen, Yu Zhao, (unknown), Wang Yf, Ming Ma, (unknown), Hualiang Jiang, Wei Wu, (unknown), Xiaowei Xu, Chengying Xie	1
2	Prevalent and Drug-Resistant Phenotypes and Genotypes of Escherichia coli Isolated from Healthy Cow’s Milk of Large-Scale Dairy Farms in China 2025 ·International Journal of Molecular Sciences ·Jiaojiao Gao, Yating Wu, (unknown), Xiaowei Xu, (unknown), (unknown), Nan Zheng, (unknown)	0
3	IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response 2025 ·Experimental Hematology and Oncology ·(unknown), Wenzhong Yan, Wang Yf, Yu Zhao, Xiaowei Xu, Yujun Chen, Chengcheng Yu, Yingnian Li, Hualiang Jiang, (unknown), Jianjun Cheng, Chengying Xie	3
4	Using Quercetin to Construct Molecularly Imprinting Polymer in the Preparation and Enrichment of Flavonol and Flavonoid Compounds 2024 ·The American Journal of Chinese Medicine ·Dandan Yang, Shuyi Li, Xiaowei Xu, (unknown), (unknown), Lian‐Di Zhou, Qi‐Hui Zhang	2
5	Longitudinal dynamic single-cell mass cytometry analysis of peripheral blood mononuclear cells in COVID-19 patients within 6 months after viral RNA clearance 2024 ·BMC Infectious Diseases ·(unknown), Shuai Zhao, (unknown), Qiuhong Liu, Fen Zhang, Zhangya Pu, Lanlan Xiao, Lingjian Zhang, (unknown), (unknown), Xiaoxin Wu, (unknown), (unknown), (unknown), (unknown), Min Xu, (unknown), Danhua Zhu, Zhongyang Xie, Xiaowei Xu	1
6	Identification of a Potential miRNA–mRNA Regulatory Network Associated With the Prognosis of HBV-ACLF 2021 ·Frontiers in Molecular Biosciences ·Shanshan Ma, Zhongyang Xie, Lingjian Zhang, Ya Yang, (unknown), Xiaoxi Ouyang, Yalei Zhao, Qiuhong Liu, Xiaowei Xu, Lanjuan Li	9
7	Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020 2021 ·Frontiers in Cellular and Infection Microbiology ·(unknown), Liang Yu, Jin Zi, Yongjun Wang, Meng Gao, (unknown), Xunhui Zhuo, Xiao Zhu, Fei Gao, (unknown), Guoqing Ying, Xiaowei Xu, Qingming Kong, Shaohong Lu, (unknown)	3
8	Thyroid Function Abnormalities in COVID-19 Patients 2021 ·Frontiers in Endocrinology ·Weibin Wang, Xingyun Su, Yongfeng Ding, Weina Fan, Weibin Zhou, Junwei Su, Zhendong Chen, Hong Zhao, Kaijin Xu, Qin Ni, Xiaowei Xu, Yunqing Qiu, Lisong Teng	61
9	Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series breakdown → 2020 ·BMJ ·Xiaowei Xu, Xiaoxin Wu, Xiangao Jiang, Kaijin Xu, Lingjun Ying, Chunlian Ma, Shibo Li, Huaying Wang, Sheng Zhang, Hainv Gao, Jifang Sheng, Hongliu Cai, Yunqing Qiu, Lanjuan Li	1497
10	Contingency management strategies of the Nursing Department in centralized rescue of patients with coronavirus disease 2019 2020 ·International Journal of Nursing Sciences ·Huafen Wang, (unknown), (unknown), Jianhua Wei, (unknown), Xiaowei Xu, (unknown), Yijun Zhang, (unknown), (unknown), Tingbo Liang	27
11	Characterization of an Artificial Liver Support System‐Related Vasovagal Reaction 2020 ·BioMed Research International ·Shanshan Ma, Zhongyang Xie, (unknown), (unknown), Lingjian Zhang, Ya Yang, (unknown), Xiaowei Xu, Lanjuan Li	0
12	The Artificial-Liver Blood-Purification System Can Effectively Improve Hypercytokinemia for COVID-19 2020 ·Frontiers in Immunology ·Jing Guo, Xia He, Shuting Wang, Liang Yu, (unknown), Jun Chen, Ding Shi, Yanfei Chen, Yan Zhang, Kaijin Xu, Xiaowei Xu, Jifang Sheng, Yunqing Qiu, Lanjuan Li	13
13	Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: Classification and regression tree analysis 2019 ·Scientific Reports ·(unknown), Feiyang Ji, Zhongyang Xie, Daxian Wu, Xiaowei Xu, Hainv Gao, Xiaoxi Ouyang, Lanlan Xiao, (unknown), Danhua Zhu, Lanjuan Li	26
14	Antibiotics-mediated intestinal microbiome perturbation aggravates tacrolimus-induced glucose disorders in mice 2019 ·Frontiers of Medicine ·Yuqiu Han, (unknown), Qi Ling, Li Wu, Pin Wu, Ruiqi Tang, Xiaowei Xu, Meifang Yang, Lijiang Zhang, (unknown), Baohong Wang, Lanjuan Li	17
15	Dysregulated Up-Frameshift Protein 1 Promotes Ulcerative Colitis Pathogenesis Through the TNFR1-NF-κB/MAPKs Pathway 2018 ·Digestive Diseases and Sciences ·Hua-Tuo Zhu, Shujun Huang, Min Yue, Wenguo Chen, Chao Lü, (unknown), Chunxiao Li, (unknown), (unknown), Xiaowei Xu, Guoqiang Xu, (unknown)	5
16	Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure: a nationwide prospective multicenter study in China 2016 ·Hepatobiliary & pancreatic diseases international ·Jiajia Chen, Jianrong Huang, Qian Yang, Xiaowei Xu, Xiaoli Liu, Shaorui Hao, Huifen Wang, Tao Han, Jing Zhang, Jianhe Gan, Zhiliang Gao, Yuming Wang, Shumei Lin, Qing Xie, Chen Pan, Lanjuan Li	50
17	Bacterial coinfection is associated with severity of avian influenza A (H7N9), and procalcitonin is a useful marker for early diagnosis 2015 ·Diagnostic Microbiology and Infectious Disease ·Meifang Yang, Hainv Gao, Jiajia Chen, Xiaowei Xu, Lingling Tang, Yida Yang, Weifeng Liang, Liang Yu, Jifang Sheng, Lanjuan Li	13
18	A Modified MELD Model for Chinese Pre-ACLF and ACLF Patients and It Reveals Poor Prognosis in Pre-ACLF Patients 2013 ·PLoS ONE ·Qi Xia, Xiahong Dai, Yimin Zhang, Yongzheng Guo, Xiaowei Xu, Qian Yang, Weibo Du, Xiaoli Liu, Yuemei Chen, Jianrong Huang, Lanjuan Li	43
19	Involvement of REST corepressor 3 in prognosis of human hepatitis B 2011 ·Acta Pharmacologica Sinica ·Jihua Xue, Min Zheng, Xiaowei Xu, Shanshan Wu, Zhi Chen, (unknown)	2
20	Fatty acid synthase inhibitors: research advances. 2009 ·Xiaowei Xu, Xiaokui Wang, Song Li	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact